Chronicle Journal: Finance

AstraZeneca sales rise 10% in a year dominated by the coronavirus

AstraZeneca has featured prominently in 2020 because of its coronavirus jab, although it has said will not profit from the vaccine during the pandemic.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.